It’s been more than a decade since Dendreon’s prostate cancer immunotherapy, Provenge, won FDA approval.
Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries.
Merck’s megablockbuster Keytruda has returned to its roots with a new indication in melanoma, the therapy area where it was first approved seven years ago.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.